- Home
- U S Acute Respiratory Distress Syndrome Ards Market
U.S. Acute Respiratory Distress Syndrome (ARDS) Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-568 | No of pages: 122 | Format:
U.S. acute respiratory distress syndrome (ARDS) market is projected to register a CAGR of 10.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
Market Segmentation:
U.S. acute respiratory distress syndrome (ARDS) market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Parenteral Oral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Industry Trends and Forecast to 2029
Some of the major factors for the market growth are:
Increasing prevalence and incidence of acute lung injury
Acceleration in a patient pool of COVID-19 with ARDS
Market Players:
The key market players in U.S. acute respiratory distress syndrome (ARDS) market are listed below:
Gilead Sciences, Inc.
Terumo Medical Corporation
Getinge AB.
Medtronic
LivaNova PLC
Fresenius SE & Co. KGaA
Drgerwerk AG & Co. KGaA
F. Hoffmann-La Roche Ltd
Fisher & Paykel Healthcare Limited.
Hamilton Medical
NIPRO
Pfizer Inc.
ResMed
Smiths Medical
WEINMANN Emergency Medical Technology GmbH + Co. KG
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 12
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 MULTIVARIATE MODELLING 21
2.7 CAUSE LIFELINE CURVE 22
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.9 DBMR MARKET POSITION GRID 24
2.10 MARKET END USER COVERAGE GRID 25
2.11 VENDOR SHARE ANALYSIS 26
2.12 SECONDARY SOURCES 27
2.13 ASSUMPTIONS 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 30
4.1 PESTEL ANALYSIS 31
4.2 PORTER'S FIVE FORCES MODEL 32
4.3 PIPELINE ANALYSIS 33
5 INSURANCE REIMBURSEMENT 35
5.1 CENTER FOR MEDICARE SERVICES (CMS)ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 35
5.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 36
5.3 ABBOTT CODING GUIDE FOR ECMO 36
5.4 CERN HEALTH INSURANCE SCHEME 37
5.5 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) (MEDICARE & MEDICAID) 37
5.6 AMERICAN HOSPITAL ASSOCIATION 37
5.7 CONCLUSION 37
6 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS 38
6.1 REGULATION IN U.S. 38
6.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA 38
6.3 LABELING OF MODIFIED DEVICES 40
7 COUNTRY SUMMERY 42
8 MARKET OVERVIEW 43
8.1 DRIVERS 45
8.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 45
8.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS 45
8.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS 46
8.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES 46
8.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 47
8.2 RESTRAINTS 47
8.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS 47
8.2.2 HIGH COST OF DEVICE AND TREATMENTS 48
8.2.3 LACK OF SKILLED WORKFORCE 48
8.3 OPPORTUNITIES 49
8.3.1 GROWING GERIATRIC POPULATION 49
8.3.2 RISING HEALTHCARE EXPENDITURE 50
8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 50
8.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME 51
8.4 CHALLENGES 51
8.4.1 STRINGENT RULES & REGULATIONS 51
8.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES 52
9 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE 53
9.1 OVERVIEW 54
9.2 CORONAVIRUS DISEASE 2019 (COVID-19) 57
9.3 SEPSIS 57
9.4 INHALATION OF HARMFUL SUBSTANCES 58
9.5 SEVERE PNEUMONIA 58
9.6 OTHERS 59
10 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE 60
10.1 OVERVIEW 61
10.2 DIAGNOSIS 64
10.2.1 IMAGING TESTS 65
10.2.1.1 CHEST X-RAY 65
10.2.1.2 CT SCAN 65
10.2.1.3 ULTRASOUND 65
10.2.1.4 OTHERS 65
10.2.2 BLOOD TEST 65
10.2.3 RESPIRATORY RATE 66
10.2.4 SPO2 TEST 66
10.2.5 OTHERS 66
10.3 TREATMENT 66
10.3.1 MECHANICAL VENTILATION 67
10.3.1.1 HIGH-FLOW NASAL O2 67
10.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 67
10.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE 68
10.3.1.4 PRONE POSITIVE VENTILATION 68
10.3.1.5 OTHERS 68
10.3.2 CORTICOSTEROIDS 68
10.3.2.1 METHYLPREDNISOLONE 68
10.3.2.2 DEXAMETHASONE 68
10.3.2.3 OTHERS 68
10.3.3 ANTIVIRAL MEDICATION 69
10.3.3.1 REMDESIVIR 69
10.3.3.2 COMBINATION DRUGS 69
10.3.3.3 OTHERS 69
10.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69
10.3.5 TOCILIZUMAB 69
10.3.6 OTHERS 69
11 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION 70
11.1 OVERVIEW 71
11.2 PARENTERAL 74
11.2.1 INTRAVENOUS 74
11.2.2 INTRAMUSCULAR 75
11.3 ORAL 75
11.4 OTHERS 76
12 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER 77
12.1 OVERVIEW 78
12.2 HOSPITALS 81
12.3 SPECIALTY CLINICS 81
12.4 HOME HEALTHCARE 81
12.5 OTHERS 82
13 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL 83
13.1 OVERVIEW 84
13.2 DIRECT TENDER 87
13.3 HOSPITAL PHARMACY 87
13.4 RETAIL PHARMACY 87
13.5 ONLINE PHARMACY 88
14 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE 89
14.1 COMPANY SHARE ANALYSIS: U.S 89
15 SWOT ANALYSIS 90
16 COMPANY PROFILE 91
16.1 GILEAD SCIENCES INC. 91
16.1.1 COMPANY SNAPSHOT 91
16.1.2 REVENUS ANALYSIS 91
16.1.3 PRODUCT PORTFOLIO 92
16.1.4 RECENT DEVELOPMENT 92
16.2 TERUMO CORPORATION 93
16.2.1 COMPANY SNAPSHOT 93
16.2.2 REVENUS ANALYSIS 93
16.2.3 PRODUCT PORTFOLIO 94
16.2.4 RECENT DEVELOPMENT 94
16.3 GETINGE AB 95
16.3.1 COMPANY SNAPSHOT 95
16.3.2 REVENUS ANALYSIS 95
16.3.3 PRODUCT PORTFOLIO 96
16.3.4 RECENT DEVELOPMENT 96
16.4 LIVANOVA PLC 97
16.4.1 COMPANY SNAPSHOT 97
16.4.2 REVENUE ANALYSIS 97
16.4.3 PRODUCT PORTFOLIO 98
16.4.4 RECENT DEVELOPMENTS 98
16.5 MEDTRONIC 99
16.5.1 COMPANY SNAPSHOT 99
16.5.2 REVENUE ANALYSIS 99
16.5.3 PRODUCT PORTFOLIO 100
16.5.4 RECENT DEVELOPMENTS 100
16.6 DRGERWERK AG & CO. KGAA 101
16.6.1 COMPANY SNAPSHOT 101
16.6.2 REVENUE ANALYSIS 101
16.6.3 PRODUCT PORTFOLIO 102
16.6.4 RECENT DEVELOPMENTS 102
16.7 F. HOFFMANN-LA ROCHE LTD 103
16.7.1 COMPANY SNAPSHOT 103
16.7.2 RECENT ANALYSIS 103
16.7.3 PRODUCT PORTFOLIO 104
16.7.4 RECENT DEVELOPMENTS 104
16.8 FISHER & PAYKEL HEALTHCARE LIMITED 105
16.8.1 COMPANY SNAPSHOT 105
16.8.2 REVENUE ANALYSIS 105
16.8.3 PRODUCT PORTFOLIO 106
16.8.4 RECENT DEVELOPMENTS 106
16.9 FRESENIUS SE & CO. KGAA 107
16.9.1 COMPANY SNAPSHOT 107
16.9.2 REVENUS ANALYSIS 107
16.9.3 PRODUCT PORTFOLIO 108
16.9.4 RECENT DEVELOPMENTS 108
16.10 HAMILTON MEDICAL 109
16.10.1 COMPANY SNAPSHOT 109
16.10.2 PRODUCT PORTFOLIO 109
16.10.3 RECENT DEVELOPMENT 109
16.11 NIPRO 110
16.11.1 COMPANY SNAPSHOT 110
16.11.2 REVENUS ANALYSIS 110
16.11.3 PRODUCT PORTFOLIO 111
16.11.4 RECENT DEVELOPMENT 111
16.12 PFIZER INC. 112
16.12.1 COMPANY SNAPSHOT 112
16.12.2 REVENUS ANALYSIS 112
16.12.3 PRODUCT PORTFOLIO 113
16.12.4 RECENT DEVELOPMENT 113
16.13 RESMED 114
16.13.1 COMPANY SNAPSHOT 114
16.13.2 REVENUE ANALYSIS 114
16.13.3 PRODUCT PORTFOLIO 115
16.13.4 RECENT DEVELOPMENT 115
16.14 SMITHS MEDICAL 116
16.14.1 COMPANY SNAPSHOT 116
16.14.2 REVENUS ANALYSIS 116
16.14.3 PRODUCT PORTFOLIO 117
16.14.4 RECENT DEVELOPMENTS 117
16.15 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 118
16.15.1 COMPANY SNAPSHOT 118
16.15.2 PRODUCT PORTFOLIO 118
16.15.3 RECENT DEVELOPMENT 118
17 QUESTIONNAIRE 119
18 RELATED REPORTS 122
Segmentation
Short Description
U.S. Acute Respiratory Distress Syndrome (ARDS) Market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and others), Industry Trends and Forecast to 2029
Market Definition:
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are already hospitalized for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the lungs' tiny, elastic air sacs called alveoli. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illness develops ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and depending on the severity of the illness, patients surviving the syndrome becomes hard. Severe illness or injury causing damage to the membrane sacs of the lungs leads to ARDS. The most common underlying causes for the said diseases include sepsis, inhalation of harmful substances, severe pneumonia, head, chest, or another major injury, coronavirus disease 2019 (COVID-19), and others.
Market Segmentation:
U.S. acute respiratory distress syndrome (ARDS) market is categorized into five notable segments: cause, type, route of administration, end users, and distribution channel.
On the basis of cause, the U.S. acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others
On the basis of type, the U.S. acute respiratory distress syndrome (ARDS) market is segmented into diagnosis and treatment
On the basis of route of administration, the U.S. acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral, and others
On the basis of end-users, the U.S. acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare, and others
On the basis of distribution channel, the U.S. acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others
Market Players
The key market players operating in the U.S. acute respiratory distress syndrome (ARDS) market are listed below:
Gilead Sciences, Inc.
Terumo Medical Corporation
Getinge AB.
Medtronic
LivaNova PLC
Fresenius SE & Co. KGaA
Drgerwerk AG & Co. KGaA
F. Hoffmann-La Roche Ltd
Fisher & Paykel Healthcare Limited.
Hamilton Medical
NIPRO
Pfizer Inc.
ResMed
Smiths Medical
WEINMANN Emergency Medical Technology GmbH + Co. KG
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.